International Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1
|
|
- Martin Curtis
- 6 years ago
- Views:
Transcription
1 Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia
2 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), as well as the company s Annual Report 2014 and Form 20-F, both filed with the SEC in February 2015, and presentations made, written information released, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain forward-looking statements. Words such as believe, expect, may, will, plan, strategy, prospect, foresee, estimate, project, anticipate, can, intend, target and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to: Statements of targets, plans, objectives or goals for future operations, including those related to Novo Nordisk s products, product research, product development, product introductions and product approvals as well as cooperation in relation thereto Statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures Statements regarding future economic performance, future actions and outcome of contingencies such as legal proceedings, and Statements regarding the assumptions underlying or relating to such statements. These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors, including those described in this presentation, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results include, but are not limited to, global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, product recall, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Novo Nordisk s products, introduction of competing products, reliance on information technology, Novo Nordisk s ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, failure to recruit and retain the right employees, and failure to maintain a culture of compliance. Please also refer to the overview of risk factors in Be aware of the risk on p of the Annual Report 2014 on the company s website novonordisk.com. Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this presentation, whether as a result of new information, future events or otherwise. Important drug information Victoza (liraglutide 1.2 mg & 1.8 mg) is approved for the management of type 2 diabetes only Saxenda (liraglutide 3 mg) is approved in the US and EU for the treatment of obesity only
3 Slide 3 International Operations is a vast and diverse region of increasing importance to Novo Nordisk Key facts about International Operations (IO) Six business areas spanning 141 countries Sales: 11 bdkk YTD 1 (14% of Novo Nordisk sales) 5-year sales growth: 17% CAGR Share of Novo Nordisk growth (YTD 1 ): 27% Diabetes: 77%; Biopharm: 23% of sales Insulin volume market share: 55% (MAT) Six business areas; 141 countries; 5,128 employees 2 1 YTD = First nine months of 2015; reported sales; 2 Full time employee equivalents in Novo Nordisk s International Operations (excludes employees in headquarter and manufacturing) as of October 2015 Source: IMS monthly MAT volume figures, IMS only covers 13 markets in IO (retail data) Note: New IO structure. Australia and New Zealand are included in reported IO numbers until end 2015 whereafter these countries will be part of Region Pacific
4 Slide 4 Half of the people with diabetes live in IO and the number is growing faster than elsewhere in the world Million people Growth in number of people with diabetes estimated to continue CAGR 1 7.0% 1 st edition th edition nd edition th edition rd edition th edition th edition E 2030E 2040E Share of people 100% 80% 60% 40% 0% Distribution of people with diabetes International Operations China Japan & Korea Europe North America 49% 50% 56% E 1 CAGR for 15-year period. Note: For each edition prevalence for intervening years extrapolated by applying a constant growth factor. Source: IDF Diabetes Atlas edition 1-7, year , respectively. Note: age group Source: International Diabetes Foundation: Diabetes Atlas edition 1 and 7, year 2000 and 2015 respectively (regional breakdown does not reflect the Novo Nordisk regional breakdown entirely)
5 Slide 5 Novo Nordisk value growth in International Operations is driven by modern insulin tmu International Operations insulin market by segments CAGR volume 1 : 12.1% CAGR value 1 : 9.6% Fast-acting Premix Long-acting Device penetration Penetration 100% % 60% 40% 0% 1 CAGR for 5-year period Note: IMS only covers the following 13 markets in IO (retail data): Algeria, Argentina, Australia, Brazil, Colombia, Egypt, India, Mexico, New Zealand, Russia, Saudi Arabia, South Africa and Turkey Source: IMS Monthly MAT volume and value (DKK) figures DKK billion International Operations diabetes care sales development Diabetes care sales 9M % 16% Modern GLP-1 Human insulin 2 insulin 2 Includes new-generation insulin 3 Predominantly oral antidiabetic products, devices and needles Source: Novo Nordisk historical sales data, local currencies 14% 5% Share of growth Other Diabetes diabetes care sales care sales 3 9M 2015
6 Slide 6 Growth in IO in the first nine months of 2015 is driven by Latin America and the Middle East Sales as reported First nine months of 2015 Growth analysis First nine months of 2015 Local currencies Growth Share of growth Middle East & Russia 22% 10% 39% 14% 5% 25% 51% 16% Africa +15% India & Southeast Asia +31% Latin America +33% Middle East & Russia 14% 29% Latin America 46% 45% Africa 10% 14% India & Southeast Asia 12% 12% Total sales 19% 100% Sales of DKK 11.0 billion (+23%) Note: Breakdown excludes sales in Australia and New Zealand of DKK 842 million, which going forward will be part of Region Pacific
7 Slide 7 The vastness and complexity of IO is managed by market segmentation and the application of a uniform strategy 141 countries Three market tiers One strategy Note: Market tier plot is illustrative and only includes a sample of countries from each tier
8 Slide 8 IO markets are segmented in three tiers IO market tier plot Maturity High Brazil Mexico Vietnam India Turkey Colombia Myanmar Tier 1 Iran Uruguay Tier 2 Ghana Low Tier 3 Short-term Mid-term Long-term Return on Investment (ROI) Additional parameters on which IO markets differ Aside from the maturity level and investment horizon, IO markets differ on four parameters: Level of GDP and growth potential Level of healthcare coverage Level of risk and stability Level of Novo Nordisk presence and organisational maturity Note: Market tier plot is illustrative and only includes a sample of countries from each tier
9 Slide 9 The IOAmbition 2017 is the midterm strategy for realising the growth potential of International Operations IOAmbition 2017 Must Win Battles Launch excellence IO will have more than 100 product launches during Better treatment IO will improve patients lives by offering the best treatment possible and by constantly striving to have patients use the most effective treatment offered by Novo Nordisk. Access to care IO will focus on overcoming obstacles for patients to get access to Novo Nordisk s products. Best people, best organisation IO will attract, retain and develop committed people and build an organisation that outperforms competition.
10 Slide 10 Tresiba and Ryzodeg launches have driven market share gains in Latin America Tresiba is steadily increasing Novo Nordisk s modern basal insulin market share in Brazil % value market share 100% Tresiba Levemir glargine Ryzodeg has rapidly increased Novo Nordisk s modern premix market share in Mexico % value market share 100% Ryzodeg NovoMix Lispro Mix 80% 76% 80% 60% 60% 61% 40% 40% 0% % 11% % Aug % 15% 2015 Source: IMS monthly tember 2015 value figures, modern and new-generation insulin only Source: IMS monthly tember 2015 value figures, modern and new-generation insulin only
11 Slide 11 Upgrading to better treatment with modern insulin drives sales increase in Vietnam 100% 80% 60% 40% Split between Novo Nordisk human and modern insulin sales in Vietnam Share of insulin sales Modern insulin Human insulin Activities to expand coverage for modern insulin in Vietnam Reinforcement of product, scientific and value communication knowledge internally Dedicated scientific symposiums to increase awareness and understanding of modern insulins externally Local cost effectiveness workshops for payers and prescribers 0% E 2015E = estimated full year sales for 2015 Source: Novo Nordisk sales volume data
12 Slide 12 Novo Nordisk aims to close the gap in access to care in IO, particularly in least developed markets Seven Diabetes Support Centres launched in Ghana Base of the Pyramid programme aims to improve access to care in low income markets Business development initiative aiming to increase access to care in low income countries through interventions to: 1. Increase awareness of diabetes 2. Ensure early diagnosis of diabetes 3. Educate healthcare professionals to manage diabetes 4. Increase availability and accessibility of diabetes care products 5. Improve adherence through patient education and support Projects launched in Ghana, India, Kenya and Nigeria Free screening at Diabetes Support Centre in Accra, Ghana, April 2014
13 Slide 13 Concluding remarks Novo Nordisk is gaining insulin value market share in IO after a period of decline Value MS (%) 60% 50% 40% 30% Novo Nordisk Sanofi Eli Lilly Biocon 49% 33% IO key takeaways Steadily increasing value market share of 49% in IO driven by new product launches and modern insulin penetration 67% of insulin IO sales in 2015 are either modern or newgeneration insulin compared to 57% in Novo Nordisk product launches planned in IO for % 0% % 1% 2015 Source: IMS Monthly MAT value figures, numbers do not add up to 100% due to smaller insulin manufacturers. IMS only covers the following 13 markets in IO (retail data): Algeria, Argentina, Australia, Brazil, Colombia, Egypt, India, Mexico, New Zealand, Russia, Saudi Arabia, South Africa and Turkey
Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationSlide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO
Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company
More informationOral semaglutide and production expansion. Henrik Wulff EVP Product Supply. Peter Kristensen SVP Global Development
YASMIN FIEDLER Germany Yasmin has type 1 diabetes Slide 1 Oral semaglutide and production expansion Henrik Wulff EVP Product Supply Peter Kristensen SVP Global Development Slide 2 Forward-looking statements
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationSlide 1. Winning with GLP-1. Lars Fruergaard Jørgensen President and CEO. ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes
Slide 1 Lars Fruergaard Jørgensen President and CEO ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the
More informationSlide 1. Investor Presentaton Jefferies Global Healthcare Conference. New York, 7 June Shanghai part of Cities Changing Diabetes
Slide 1 Investor Presentaton Jefferies Global Healthcare Conference New York, 7 June 2016 Shanghai part of Cities Changing Diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationSlide 1. Jefferies 2014 Global Healthcare Conference 5-June Karsten Munk Knudsen CVP of Finance & IT at NNI
Slide 1 Jefferies 2014 Global Healthcare Conference 5-June-2014 Karsten Munk Knudsen CVP of Finance & IT at NNI Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide
More informationBusiness update InvestorDagen
Slide 1 Business update 28 November 2017 Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities
More informationSlide 1. First six months of London 10 August Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan
Slide 1 First six months of 2017 London 10 August 2017 Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook
More informationSlide 1. Investor presentation. Copenhagen 1 November 2018
Slide 1 Investor presentation Copenhagen 1 November 2018 Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type 1 diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Highlights
More informationSlide 1. Investor presentation Full year London, 4 February Shanghai part of Cities Changing Diabetes
Slide 1 Investor presentation Full year 2015 London, 4 February 2016 Shanghai part of Cities Changing Diabetes Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide
More informationSlide 1. First nine months of London 2 November Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan
Slide 1 First nine months of 2017 London 2 November 2017 Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook
More informationSlide 1. Investor presentation. Meet the Management London, 9 August 2018
Slide 1 Investor presentation Meet the Management London, 9 August 2018 Manato diagnosed with type 1 diabetes Shirley Ohara, Adelia Stewart has type 2 diabetes Kanagawa, Japan New Orleans, Louisiana, US
More informationSlide 1. First three months of 2018 Conference call
Slide First three months of 208 Conference call Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Agenda Highlights
More informationInvestor conference call First quarter of 2016
Slide 1 Investor conference call First quarter of 2016 Shanghai part of Cities Changing Diabetes Slide 2 Agenda Highlights and key events By Lars Rebien Sørensen, president and CEO Sales update By Lars
More informationSlide 1. Conference call Full year 2018
Slide Conference call Full year 208 Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished
More informationType 1 Diabetes (T1D) Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research
Type 1 Diabetes (T1D) Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research "Type 1 diabetes market size was valued at USD 25.52 billion in 2016 and is expected to exhibit rewarding
More informationDesigning a Smoke-Free Future
Designing a Smoke-Free Future Morgan Stanley Global Consumer & Retail Conference New York, November 14, 2017 Jacek Olczak Chief Financial Officer Martin King President, Asia Region Forward-Looking and
More informationSlide 1. R&D strategy. Mads Krogsgaard Thomsen EVP and Chief Science Officer. ZIHAO LI AND HIS MOTHER BING HAN, China Zihao has haemophilia A
Slide 1 R&D strategy Mads Krogsgaard Thomsen EVP and Chief Science Officer ZIHAO LI AND HIS MOTHER BING HAN, China Zihao has haemophilia A R&D strategy Slide 2 Forward-looking statements Novo Nordisk s
More informationNOVO NORDISK. Analyst: Recommendation: HOLD DATE: Industry: Drug manufacturers
NOVO NORDISK Analyst: Recommendation: HOLD DATE: 11.11.2015 Industry: Drug manufacturers Share price 375,00 DKK Homepage www.novonordisk.com Ticker NVO Number of shares (000) 2.563.800 Target price 406,14
More informationSlide 1. Full year London 5 February Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan
Slide 1 Full year 2017 London 5 February 2018 Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide
More informationNovo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 4% in local currencies in the first six months of 2018
report for the period 1 January 2018 to 30 June 2018 8 August 2018 Novo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 4% in local currencies in the first six months of 2018
More informationAnnual Stockholder Meeting May 30, confidently live life with ease
Annual Stockholder Meeting May 30, 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationTELECONFERENCE FY February 2015
TELECONFERENCE FY 2014 5 February 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationNovo-Nordisk As (NVO-NYSE) Analyst Note
February 03, 2015 Novo-Nordisk As (NVO-NYSE) Analyst Note NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 02/10/2014 Current Price (02/02/15) $44.73 Target Price $47.00
More informationGlobal Hearing Aid Battery Market: Analysis By Battery Type, By Region, By Country: Trends, Opportunities, Restraints (2018 Edition) Forecast to 2022
Global Hearing Aid Battery Market: Analysis By Battery Type, By Region, By Country: Trends, Opportunities, Restraints (2018 Edition) Forecast to 2022 By Value (In Million USD) By Volume (In Million Units)
More informationInvestor Update May 2016
Investor Update May 2016 Novo Nordisk poised for growth through helping care for rising global diabetes epidemic On Marsico Capital Management s trip to Australia in March, Portfolio Managers Tom Marsico
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationFinancial report for the period 1 January 2017 to 30 September November Novo Nordisk A/S Investor Relations
report for the period 1 January 2017 to 30 September 2017 1 November 2017 Novo Nordisk increased reported operating profit by 5% in the first nine months of 2017 Reported sales increased by 2% to DKK 83.7
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationMAGAZINE CAMILLA SYLVEST JOINS EXECUTIVE MANAGEMENT NEW INTERESTING RESULTS WITH SEMAGLUTIDE
MAGAZINE NO 3 217 QUARTERLY INVESTOR UPDATE CAMILLA SYLVEST JOINS EXECUTIVE MANAGEMENT NEW INTERESTING RESULTS WITH SEMAGLUTIDE VICTOZA APPROVED IN THE US AND THE EU AS THE ONLY GLP-1 PRODUCT TO PREVENT
More informationNet profit increased by 1% to DKK 38.6 billion and diluted earnings per share increased by 4% to DKK
report for the period 1 January 2018 to 31 December 2018 1 February 2019 Novo Nordisk's operating profit decreased by 4% in Danish kroner and increased by 3% in local currencies in 2018 Operating profit
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationJEFFERIES 2016 HEALTHCARE CONFERENCE. June 2016
JEFFERIES 2016 HEALTHCARE CONFERENCE June 2016 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationTELECONFERENCE Q November 2015
TELECONFERENCE Q3 2015 4 November 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationshare SAXENDA LAUNCHED IN THE US FOR THE TREATMENT OF OBESITY POSITIVE TRIAL RESULTS FOR GLP-1 TABLET FIRST QUARTER: OPERATING PROFIT INCREASED BY 17%
share QUARTERLY INVESTOR UPDATE MAY 21 QUARTERLY INVESTOR UPDATE MAY 21 SAXENDA LAUNCHED IN THE US FOR THE TREATMENT OF OBESITY POSITIVE TRIAL RESULTS FOR GLP-1 TABLET FIRST QUARTER: OPERATING PROFIT INCREASED
More informationGlobal EHS Resource Center
Global EHS Resource Center Understand environmental and workplace safety requirements that affect your global operations. 800.372.1033 bna.com/gelw Global EHS Resource Center This comprehensive research
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationMore information at
Report Information More information at https://www.htfmarketreport.com/reports/1288313 Global Homeopathic Products Market Professional Survey Report 2018 Report Code: HTF1288313 Pages: 111 Price: 1-User
More informationGlobal Transcatheter Mitral Valve Repair and Replacement (TMVR) Market: Analysis By Region, By Country: Opportunities and Forecast ( )
Global Transcatheter Mitral Valve Repair and Replacement (TMVR) Market: Analysis By Region, By Country: Opportunities and Forecast (2017-2022) By Region- North America, Europe, APAC and RoW By Country
More informationGlobal Stevia Extracts Market Analysis By Type (Dried, Leaves, Powder, Liquid), Application, Region, Country: Opportunities and Forecast ( )
Global Stevia Extracts Market Analysis By Type (Dried, Leaves, Powder, Liquid), Application, Region, Country: Opportunities and Forecast (2017-2022) Analysis By Type - Fresh/Dried leaves, Stevia powder,
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationInvestor Day EEMA Region Lausanne, September 29, Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free
Investor Day EEMA Region Lausanne, September 29, 2016 Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free Agenda Overview and Key Results Vision and Strategic Pillars
More informationFY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
More informationOBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss
OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information
More informationCountry Coverage. Company Coverage
Global Heart Valve Devices Market: Analysis By Procedure (Replacement & Repair), Replacement Procedure By Technique (Mechanical, Bioprosthetic & TAVR), Repair Procedure By Technique (Surgical, Balloon
More informationSlide 1. First nine months of Copenhagen 1 November Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan
Slide First nine months of 207 Copenhagen November 207 Manato Ohara, diagnosed with type diabetes Kanagawa, Japan Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook
More informationNovo Nordisk increased reported operating profit by 8% in the first six months of 2017 Sales increased by 4% measured in Danish kroner
report for the period 1 January 2017 to 30 June 2017 9 August 2017 Novo Nordisk increased reported operating profit by 8% in the first six months of 2017 Sales increased by 4% measured in Danish kroner
More informationSlide 1. Investor presentation First nine months of 2018
Slide Investor presentation First nine months of Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Agenda Highlights
More informationMolecular Diagnostics Market Share, Size, Analysis, Growth, Trends and Forecasts, 2016 to 2024 Hexa Research
Molecular Diagnostics Market Share, Size, Analysis, Growth, Trends and Forecasts, 2016 to 2024 Hexa Research " Projected to grow at a CAGR of almost 9% from 2016 to 2024, the molecular diagnostics market
More informationMonitoring EU Agri-Food Trade: Development until February 2018
Monitoring EU Agri-Food Trade: Development until February 2018 February 2018: a further increase in EU agri-food trade surplus The monthly value of EU agri-food exports in February 2018 decreased slightly
More informationTamsulosin Hydrochloride 0.4 mg Capsule
Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule
More informationGlobal Invisible Braces Market: Trends, Opportunities and Forecasts ( )
Global Invisible Braces Market: Trends, Opportunities and Forecasts (2016-2021) By Types Clear Aligners, Ceramic, Lingual By Region Americas, Europe, Middle East, Africa, Asia-Pacific By Country- USA,
More informationCowen Investor Conference March confidently live life with ease
Cowen Investor Conference March 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationThe acquisition of Fortitech
The acquisition of Fortitech Accelerating DSM s strategy to become a full solutions provider in food ingredient blends Investor Relations 8 November 2012 Overview Fortitech at a glance Acquisition rationale
More informationChronic Care Coloplast Meet the Management London 2017 Kristian Villumsen, EVP Chronic Care Edmond Veome, SVP Chronic Care North America
Chronic Care Coloplast Meet the Management London 2017 Kristian Villumsen, EVP Chronic Care Edmond Veome, SVP Chronic Care North America Chronic Care represents more than 75% of Coloplast sales and we
More informationA GLOBAL LEADER IN PERSONALIZED NUTRITION
A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking
More informationGlobal Cosmetic Dentistry Market Research Report 2018
Report Information More information from: https://www.wiseguyreports.com/reports/3029111-global-cosmetic-dentistry-market-research-report- 2018 Global Cosmetic Dentistry Market Research Report 2018 Report
More informationTELECONFERENCE Q August 2015
TELECONFERENCE Q2 2015 19 August 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationSAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB
Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0166BDB Publication Date: January 2013 GlobalData. This report is a licensed product
More informationDiagnostics for the early detection and prevention of colon cancer. Leerink Swann Global Health Care Conference February 2015
Diagnostics for the early detection and prevention of colon cancer Leerink Swann Global Health Care Conference February 2015 Safe Harbor Statement Certain statements made in this news release contain forward-looking
More informationAsia-Pacific Bariatric Surgery Devices Market Outlook to 2020
Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List
More informationConsolidated: Financial Summary
FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating
More informationSAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0165BDB Publication Date: January 2013 GlobalData. This report
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationGlobal Dental Implant Market Research Report 2018
Report Information More information from: https://www.wiseguyreports.com/reports/3220035-global-dental-implant-market-research-report-2018 Global Dental Implant Market Research Report 2018 Report / Search
More informationFor personal use only
Sirtex Medical Limited (ASX:SRX) Macquarie Inaugural Annual Emerging Healthcare Conference Mr Gilman Wong, CEO Mr Darren Smith, CFO Dr David Cade, CMO Wednesday, 10 October 2012 Macquarie Securities Group
More informationGlobal In-Vitro-Fertilization Market: Trends and Opportunities ( )
Global In-Vitro-Fertilization Market: Trends and Opportunities (2015-2019) Global In-Vitro-Fertilization Market: Trends and Opportunities (2015-2019) BioPortfolio has been marketing business and market
More informationCYCLOTRONS WORLD MARKET REPORT & DIRECTORY EDITION TOC and Summary USED IN NUCLEAR MEDICINE MARKET DATA, COMPANIES PROFILES.
CYCLOTRONS USED IN NUCLEAR MEDICINE WORLD MARKET REPORT & DIRECTORY MARKET DATA, COMPANIES PROFILES TOC and Summary EDITION 2015 A report written by Paul-Emmanuel Goethals & Richard Zimmermann Page 1/5
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationAstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes
AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance Becoming Global Leaders In Diabetes 19th December 2013 Cautionary Statement Regarding Forward-Looking Statements In order,
More informationResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference
ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationGlobal End Stage Renal Disease (ESRD) Market With Focus on Dialysis Market ( Edition) July 2017
Global End Stage Renal Disease (ESRD) Market With Focus on Dialysis Market (2017-2021 Edition) July 2017 Scope of the Report Global End Stage Renal Disease Market The report titled Global End Stage Renal
More informationMichael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation
Michael L. Levitz Chief Financial Officer November 15, 2017 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationSlide 1. First six months of Copenhagen 8 August 2018
Slide First six months of 208 Copenhagen 8 August 208 Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Agenda Highlights
More informationInvestor presentation Full year 2014
Slide Investor presentation Full year 24 Mexico City part of Cities Changing Diabetes Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide 3 Forward-looking statements
More informationTreatment of visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO):
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Treatment of visual impairment due to macular edema secondary to branch retinal
More informationSlide 1. Investor presentation First three months of 2018
Slide Investor presentation First three months of 208 Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Agenda Highlights
More informationGlobal Coverage. Regional Coverage. Country Coverage Company Coverage
Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) By Type- ALD and NAFLD ALD Stages - Alcoholic Steatosis
More informationSlide 1. Full year Copenhagen, 2 February Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan
Slide Full year 206 Copenhagen, 2 February 207 Manato Ohara, diagnosed with type diabetes Kanagawa, Japan Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide 3
More informationInvestor presentation Full year 2016
Slide Investor presentation Full year 26 Manato Ohara, diagnosed with type diabetes Kanagawa, Japan Slide 2 Forward-looking statements o Nordisk s reports filed with or furnished to the US Securities and
More informationOur future workforce. Flemming Dahl, Senior Vice President and Head of Quality, Novo Nordisk
Our future workforce Flemming Dahl, Senior Vice President and Head of Quality, Novo Nordisk ISPE Nordic 17. Nov. 2016 2 Who am I? Head of Quality in Novo Nordisk 48 years Danish Married 5 Children [7-19]
More informationSleep apnea devices Market Research Report- Global Forecast To 2022
Report Information More information from: https://www.marketresearchfuture.com/reports/2061 Sleep apnea devices Market Research Report- Global Forecast To 2022 Report / Search Code: MRFR/HC/1529-HCRR Publish
More informationInvestor Presentation. Q October 26, 2017
Investor Presentation Q1 2018 October 26, 2017 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private
More informationINVESTOR PRESENTATION JEFFERIES 2013 HEALTHCARE CONFERENCE. June 2013
INVESTOR PRESENTATION JEFFERIES 2013 HEALTHCARE CONFERENCE June 2013 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events
More informationo Dental Implants Market By Material, Type, Structure Global Forecast To 2022 Report ID: MRDH Publishing Date: July, 2017
o Dental Implants Market By Material, Type, Structure Global Forecast To 2022 Report ID: MRDH-10401 Publishing Date: July, 2017 Sr. No. License Type Price 1 Single User License $4,175.00 2 Multiple User
More informationJanuary 2017 Investor Presentation. confidently live life with ease
January 2017 Investor Presentation confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationFinancial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
More informationThis is a licensed product of Ken Research and should not be copied
1 TABLE OF CONTENTS 1. The US Diabetes Care Devices Market Introduction 1.1. What is Diabetes and it s Types? 2. The US Diabetes Care Devices Market Size, 2007-2013 3. The US Diabetes Care Devices Market
More information